Plain English Summary
Background and study aims
The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. HIV attacks and weakens the immune system, making it more difficult for a sufferer to fight infections. It is a highly contagious disease, through bodily fluids such as blood, semen and vaginal fluids. It is particularly common in sub-Saharan Africa and it is especially important that people in these regions are tested for HIV in order to minimise the spread of the disease. Wide roll out of availability of HIV tests has led to increases in numbers of people getting tested and starting on antiretroviral treatment (ART) in sub-Saharan Africa. Despite such remarkable progress, men continue to lag behind in HIV testing, including men in well-established relationships where HIV transmission is still surprisingly high. It is therefore important to investigate techniques to increase the number of men who are tested and can be linked into care (if they have HIV) or HIV prevention for men. The aim of this study is to compare the effectiveness of a range of interventions (programs) to encourage men in relationships to get tested for HIV and to link to a care or prevention service.
Who can participate?
All women attending their first antenatal clinic of a participating health clinic and their male partners.
What does the study involve?
36 clinic days across the three participating clinics are randomly allocated to one of seven groups. After agreeing to take part in the study, women complete a 10 minute interview with a research assistant about the woman's and her partner’s personal information and HIV testing. For those attending clinic days in the first group, they are given a personalised invitation letter to give to her partner so that he can use the letter to come to the trial “male friendly clinic” alone or together with her. Those attending clinic days in the second group receive the letter and at least two self-test kits to give to their partners. Those in the third group receive the letter, self-test kits and a $3 incentive when they link into male friendly clinic. Those in the fourth group receive the letter, self-test kits and a $10 incentive when they link into male friendly clinic. Those in the fifth group receive the letter, self-test kits and are entered into a lottery with a 10% chance of winning $30 when they link into male friendly clinic. Those in the sixth group receive the letter, self-test kits and are followed up with a phone call to remind them to use the rests and link into male friendly clinic. Those in the final group receive two self-test kits to deliver to their male partner, a as a phone call reminder the next day and five days later. When the women in all groups return for their next appointment four weeks later, they are interviewed to find out whether they faced any problems and whether or not her partner tested and linked to the “male friendly clinic”.
What are the possible benefits and risks of participating?
Male participants who attend the “male friendly clinic” will benefit from receiving care or prevention services. There are no direct risks to participating in the study except that some participants may be uncomfortable with some of the questions that will be asked.
Where is the study run from?
Three primary health clinics in urban Blantyre (Malawi)
When is the study starting and how long is it expected to run for?
March 2016 to June 2017
Who is funding the study?
Wellcome Trust (UK) (Grant number: 105828/Z/14/Z)
Who is the main contact?
Mr Augustine Choko
Investigating interventions to increase uptake of HIV testing and linkage into care or prevention for male partners of pregnant women in antenatal clinics in Blantyre, Malawi: an adaptive Phase II multi-arm multi-stage cluster randomised trial
Partner-provided self-testing and linkage (PASTAL)
What are the most promising candidate interventions for increasing uptake of HIV testing and linkage into care or prevention for partners of pregnant women attending antenatal clinics?
London School of Hygiene & Tropical Medicine Ethics Committee, 10/06/2016
Phase II adaptive multi-arm multi-stage cluster randomised trial
Primary study design
Secondary study design
Cluster randomised trial
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
36 clinic days will be randomised in blocks of different sizes to any of the six trial arms in stage 1 of the trial. All three clinic days available in one day will be per-identified before the randomisation such that the arm recruiting at a particular clinic on particular day will be known within the randomisation sequence.
Control arm: Women receive a letter addressed to their male partners.
Intervention arm 1: Women receive a letter and self-test kits to deliver to their male partners.
Intervention arm 2: Women receive a letter and self-test kits to deliver to their male partners who will get an incentive of $3 when they link into male friendly clinic and receive HIV care or HIV prevention services.
Intervention arm 3: Women receive a letter and self-test kits to deliver to their male partners who will get an incentive of $10 when they link into male friendly clinic and receive HIV care or HIV prevention services.
Intervention arm 4: Women receive a letter and self-test kits to deliver to their male partners who will be entered into a lottery with a 10% chance of winning $30 when they link into male friendly clinic and receive HIV care or HIV prevention services.
Intervention arm 5: Women receive a letter and self-test kits to deliver to their male partners who will receive a phone call to remind them to test and link into male friendly clinic to receive HIV care or HIV prevention services.
Intervention arm 6: Women receive two self-test kits to deliver to their male partner. A phone call reminder to self-test and link into care or prevention will be made to the male partner next day and after 5 days.
Participants in all groups are interviewed at their next appointment to determine the amount of male partners who used the self-test its and went to the male friendly clinic.
Primary outcome measures
Proportion of male partners who test for HIV and link into care or prevention within 28 days is determined by the male partner undergoing HIV testing and receiving HIV care or prevention.
Secondary outcome measures
1. Proportion of women who participate in their allocated study arm is determined by face-to-face questionnaire at baseline.
2. Proportion of male partners who test for HIV within 28 days is determined by the male partner undergoing HIV testing
3. Cumulative incidence of intimate partner violence associated with each study arm is determined by audio computer assisted self-interview with women at 28 days
4. Total cost of implementing the service per study arm is determined by a costing questionnaire
Overall trial start date
Overall trial end date
Participant inclusion criteria
All women attending antenatal clinic for the first time at Ndirande PHC in urban Blantyre and their male partners
Target number of participants
120 women and 120 men per arm in stage 1. Numbers for stage 2 will be determined at interim analysis.
Participant exclusion criteria
1. Have had couple or partner testing in this pregnancy
2. Under 18 years of age
3. The man is already aware of their HIV positive status and receiving treatment
4. Subsequent ANC visit
5. Already recruited in this trial
6. Not urban Blantyre resident
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Ndirande Primary Health Centre
Trial participating centre
Zingwangwa Primary Health Centre
Trial participating centre
Bangwe Health Primary Centre
London School of Hygiene & Tropical Medicine
+44 (0)20 7636 8636
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Results will be disseminated to HIV Unit in Malawi Ministry of Health, College of Medicine in Blantyre, and through conference presentations and publication in a peer-reviewed journal.
Intention to publish date
Participant level data
To be made available at a later date
Results - basic reporting
2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/28738857